Renal Cancer Clinical Trial
Official title:
2007 - Rene: Observational Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent Radical Nefrectomy/Tumorectomy Surgery
The aim of this observational study is to gather pre and post surgery clinical data belonging to patients who underwent radical or partial nephrectomy and to evaluate the impact of the surgery on the quality of life of the patients, as well as possible relapses within a 10 year period.
A databasa was created with the intention of collecting data related to patients who underwent radical or partial nefrectomy surgery in an electronic case report form. Each patient will be followed for 10 years approximately starting from the date of surgery for a total of 2 yearly visits for the first 5 years which could then be diluted in 1 visit per year for the remaining 5 years. At each visit control exams forseen by the standard care for post surgery patients will be evalued and tha data will then be transferred into the database. Yearly, a follow up questionnaire will be sent to the patients' home in order to obtain the information relative to possible relapses. The data collected will be handled following the most strict GCPs and privacy norms. The main objectives of the study are the collection and interpretation of the scientific data with the scope of: obtaining health benefits for the patients involved and for future patients with the same type of cancer, improving the scientific knowledge on the pathology and implementing new strategies for diagnosis and therapy and evaluating the epidemiologic changes of renal neoplasia. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
| Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03203473 -
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
|
Phase 2 | |
| Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
| Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
| Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
| Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
| Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
| Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
| Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 |